Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Estimates By $0.01 EPS

Compass Therapeutics (NASDAQ:CMPX) announced its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01), Zacks reports.

Compass Therapeutics Stock Performance

CMPX stock opened at $2.90 on Friday. The company has a market capitalization of $399.01 million, a P/E ratio of -7.84 and a beta of 1.17. Compass Therapeutics has a 52-week low of $0.76 and a 52-week high of $4.08. The business has a 50-day simple moving average of $2.59 and a two-hundred day simple moving average of $1.94.

Analyst Ratings Changes

A number of brokerages recently weighed in on CMPX. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. D. Boral Capital reissued a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Tuesday. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Finally, Guggenheim initiated coverage on shares of Compass Therapeutics in a research report on Monday, February 24th. They set a “buy” rating and a $12.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $11.38.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.